Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition of red sage root and cassia twig

A technology of composition and medicine, applied in the field of medicine

Inactive Publication Date: 2012-02-22
海安江理工技术转移中心有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, the interaction between salvia miltiorrhiza or salvia miltiorrhiza extract and cassia twig or cassia twig extract is used to prepare medicines for treating cardiovascular and cerebrovascular diseases. See the report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of red sage root and cassia twig
  • Pharmaceutical composition of red sage root and cassia twig
  • Pharmaceutical composition of red sage root and cassia twig

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Preparation and assay of embodiment 1 salvia miltiorrhiza extract

[0088] 1. Preparation of Salvia Miltiorrhiza Extract

[0089] Take Danshen medicinal material, crush it into coarse powder, add water to decoct twice, add 12 times of water for the first time, add 10 times of water for the first time, each time for 2 hours, combine the decoction, filter, and concentrate the filtrate to relative density under reduced pressure 1.10~1.15 (60°C) concentrated solution, add ethanol until the alcohol content reaches 85%, refrigerate for 24 hours, filter, recover the ethanol from the filtrate until it has no alcohol smell, add hydrochloric acid to adjust the pH value to 2, shake with ethyl acetate Extracted 3 times, combined ethyl acetate solution, and evaporated to dryness. The residue was dissolved in acidic water with a pH value of 2, added to the treated polyamide column, first eluted with 2 times the column volume of water, discarded the water washing solution, and then...

Embodiment 2

[0103] Preparation and assay of embodiment 2 cassia twig extract

[0104] 1. Preparation of Cinnamon Twig Extract

[0105] Cinnamomum twig herbs are crushed to a certain particle size, put into the extraction kettle, and the SFE system is heated. The primary separation temperature is 55°C, the pressure is 30Mpa, the extraction temperature is 60°C, the secondary separation pressure is 20Mpa, and the temperature is 50°C. The time is 3 hours, and the material is discharged from the primary and secondary separation kettles.

[0106] 2. Determination of the content of cassia twig extract

[0107] Determination of cinnamic aldehyde content

[0108] Gas Chromatography:

[0109] Chromatographic conditions and system suitability test: polyethylene glycol (PEG)-20M is used as the stationary phase, and the coating concentration is 10%: the column temperature is 190°C. The theoretical plate is not less than 3000.

[0110] Preparation of the reference substance solution: Take an app...

Embodiment 3

[0116] The preparation of embodiment 3 DG tablet

[0117] Prescription one:

[0118] Salvia miltiorrhiza extract 18g (equivalent to 1kg of raw medicinal materials)

[0119] Cinnamomum twig extract 24g (equivalent to 2kg of raw medicinal materials)

[0120] 120g pregelatinized starch

[0121] Microcrystalline Cellulose 40g

[0122] Low-substituted hydroxypropyl cellulose 40g

[0123] 2% HPMC aqueous solution appropriate amount

[0124] Magnesium Stearate 6g

[0125] Carboxymethyl Starch Sodium 12g

[0126] A total of 1000 tablets were prepared

[0127] Prescription two:

[0128] Salvia miltiorrhiza extract 32.4g (equivalent to 1800g of raw medicinal materials)

[0129] Guizhi Extract 4.8g (equivalent to 400g of raw medicinal materials)

[0130] 120g pregelatinized starch

[0131] Microcrystalline Cellulose 40g

[0132] Low-substituted hydroxypropyl cellulose 40g

[0133] 2% HPMC aqueous solution appropriate amount

[0134] Magnesium Stearate 6g

[0135] Carboxy...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug compound of danshen root or the extract and cassia twig or the extract and the preparation method, the application of preparing drugs used for cardiovascular and cerebral diseases and the formulation containing the drug compound, belonging to the medical technical field. Measured by weight, the raw material drugs for preparing the effective components in the drug compound are as follow: 200 to 5000 for danshen root, 100 to 2000 for cassia twig; or 3 to 100 for the extract of the danshen root and 1 to 30 for the extract of cassia twig. The drug compound can be made into any acceptable clinical or pharmaceutical formulation; formulation for oral use or injection is preferred. The invention has the advantages that: the two drugs in the compound have the synergistic interaction function and jointly play the role of anti-myocardial ischemia, anti-thrombosis and resisting brain ischemia reperfusion injury, thereby the treating effect is improved greatly compared to singly using danshen root or the extract and cassia twig or the extract.

Description

[technical field] [0001] The invention relates to a pharmaceutical composition of salvia miltiorrhiza or its extract and cassia twig or its extract, a preparation method thereof, an application in preparing medicine for treating cardiovascular and cerebrovascular diseases, and a preparation containing the pharmaceutical composition, belonging to the technical field of medicine. [Background technique] [0002] Cardiovascular and cerebrovascular diseases include coronary heart disease, angina pectoris, myocardial infarction, congestive pulmonary heart disease, ischemic encephalopathy, cerebral thrombosis, hypertension, hyperlipidemia, etc. The main cause of these diseases is that arteriosclerosis causes narrowing of the lumen and blockage of the pipeline, which leads to insufficient blood supply to the heart and brain, causing symptoms such as dizziness, dizziness, headache, and chest tightness. In severe cases, it can lead to stroke and myocardial infarction. Cardiocerebral i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/53A61K36/54A61P9/10
Inventor 黄振华
Owner 海安江理工技术转移中心有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com